First Nebraska Trust Co acquired a new position in Becton, Dickinson and Company (NYSE:BDX – Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 27,896 shares of the medical instruments supplier’s stock, valued at approximately $4,386,000.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BDX. Auto Owners Insurance Co raised its holdings in shares of Becton, Dickinson and Company by 22,225.2% in the 4th quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock valued at $790,079,000 after buying an additional 40,528,680 shares during the period. Vanguard Group Inc. boosted its holdings in Becton, Dickinson and Company by 13.0% during the 4th quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier’s stock valued at $7,118,282,000 after acquiring an additional 4,223,149 shares during the period. State Street Corp grew its position in Becton, Dickinson and Company by 0.8% in the 4th quarter. State Street Corp now owns 13,989,132 shares of the medical instruments supplier’s stock valued at $2,714,871,000 after acquiring an additional 116,737 shares in the last quarter. First Eagle Investment Management LLC grew its position in Becton, Dickinson and Company by 16.5% in the 4th quarter. First Eagle Investment Management LLC now owns 11,646,000 shares of the medical instruments supplier’s stock valued at $2,260,139,000 after acquiring an additional 1,651,592 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA increased its stake in Becton, Dickinson and Company by 3.7% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 9,486,694 shares of the medical instruments supplier’s stock worth $1,841,083,000 after purchasing an additional 336,110 shares during the period. Hedge funds and other institutional investors own 86.97% of the company’s stock.
Insiders Place Their Bets
In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,100 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the transaction, the executive vice president directly owned 13,172 shares in the company, valued at approximately $1,918,633.52. The trade was a 7.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $146.35, for a total value of $404,511.40. Following the completion of the transaction, the chief executive officer owned 110,163 shares in the company, valued at $16,122,355.05. This trade represents a 2.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 5,189 shares of company stock worth $765,661. 0.40% of the stock is currently owned by company insiders.
Becton, Dickinson and Company Price Performance
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, beating the consensus estimate of $2.77 by $0.13. The company had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.67 billion. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The firm’s revenue was up 5.2% on a year-over-year basis. During the same period in the prior year, the firm posted $3.35 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Equities analysts expect that Becton, Dickinson and Company will post 12.53 EPS for the current fiscal year.
Becton, Dickinson and Company Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be given a dividend of $1.05 per share. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.5%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 106.33%.
Analyst Upgrades and Downgrades
Several research analysts have recently commented on BDX shares. TD Cowen lowered their price objective on shares of Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating for the company in a research note on Monday, May 4th. Royal Bank Of Canada set a $175.00 price target on shares of Becton, Dickinson and Company in a research note on Tuesday, April 14th. Wells Fargo & Company increased their price objective on Becton, Dickinson and Company from $157.00 to $161.00 and gave the company an “equal weight” rating in a research note on Friday, May 8th. Piper Sandler decreased their target price on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating for the company in a report on Friday, April 17th. Finally, Evercore set a $180.00 target price on Becton, Dickinson and Company in a research note on Monday, July 6th. Eight analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $180.93.
View Our Latest Stock Report on BDX
Becton, Dickinson and Company Company Profile
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
Read More
- Five stocks we like better than Becton, Dickinson and Company
- Popular’s Earnings Beat Shows Why This Bank Stock Keeps Climbing
- ABB’s Rotork Deal Could Put These Flow Control Stocks Back in Focus
- GE HealthCare Stock Climbs on Vital Diagnostics Demand
- Lost in Space: Why Aerospace Valuations Are Plummeting Right Now
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
